A carregar...
Structural Basis of p97 Inhibition by the Site-Selective Anticancer Compound CB-5083
Inhibition of p97, a key player in the ubiquitin-proteasome degradation pathway, has been proposed as a treatment of cancer. This concept was nearly realized recently when a potent p97 inhibitor, 1-[4-(benzylamino)-5H,7H,8H-pyrano[4,3-d]pyrimidin-2-yl]-2-methyl-1H-indole-4-carboxamide (CB-5083), was...
Na minha lista:
| Publicado no: | Mol Pharmacol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The American Society for Pharmacology and Experimental Therapeutics
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6355941/ https://ncbi.nlm.nih.gov/pubmed/30591537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.118.114256 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|